Search Results - "Toro, W."

Rare primary leiomyosarcoma of the internal jugular vein with cervical extravascular extension by Moreno-Sánchez, M, González-García, R, Moreno-García, C, Toro, W, Monje, F

“…Abstract Leiomysarcoma of intravascular origin is a rare malignant tumour of the soft tissue. We present what is, to our knowledge, the first example of one…”
Get full text

165P Health Care Resource Use (HCRU) for patients with spinal muscular atrophy (SMA) Types 2 or 3 in the UK by Reyna, S., Toro, W., Patel, A., Saleh, S., Dabbous, O.

“…Data on HCRU for patients with SMA types 2 (SMA2) and 3 (SMA3) are sparse. To our knowledge, no studies address costs from the HCP perspective. We assessed…”
Get full text

PT42 The Impact of Spinal Muscular Atrophy Type 2 on Caregivers in Argentina: Results of a Global Survey by Patel, A., Toro, W., Esquerro, M.E., Dabbous, O.

Get full text

RWD164 The Impact of Spinal Muscular Atrophy (SMA) Type 1 on Caregivers in Taiwan: Results of a Global Survey by Patel, A., Yang, K., Toro, W., Dabbous, O., Jong, Y.J.

Get full text

164P Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients by Reyna, S., Dabbous, O., Wallach, S., Patel, A., Toro, W., Ritter, S.

“…Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disease that is caused by a defect in the survival motor neuron 1 (SMN1) gene, leading to rapid…”
Get full text

EE10 The Impact of Spinal Muscular Atrophy Type 1 (SMA1) on Caregivers in Brazil: Results of a Global Survey by Patel, A, Toro, W, Martins, de Lana J, Dabbous, O, Banzzatto, Ortega A

Get full text

Totally Implantable Venous Access Device Placement by Interventional Radiologists: Are Prophylactic Antibiotics Necessary? by Covey, Anne M., MD, Toro-Pape, Franz W., BS, Thornton, Raymond H., MD, Son, Crystal, MPH, Erinjeri, Joseph, MD, PhD, Sofocleous, Constantinos T., MD, PhD, Brody, Lynn A., MD, Brown, Karen T., MD, Septkowitz, Kent A., MD, Getrajdman, George I., MD

“…Abstract Purpose To determine the rate of early infection for totally implantable venous access devices (TIVADs) placed without antibiotic prophylaxis…”
Get full text

P231 Early intervention and speed-to-effect in spinal muscular atrophy type 1 following onasemnogene abeparvovec gene replacement therapy by Toro, W., Reyna, S., Ritter, S., Patel, A., Mumneh, N., Dabbous, O.

“…Spinal muscular atrophy (SMA) type 1 is a severe genetic neuromuscular disease that is caused by a defect in the survival motor neuron 1 (SMN1) gene, and that…”
Get full text

CO177 The Burden of Spinal Muscular Atrophy Type 1 on Caregivers in Argentina: First Results of a Global Survey Launched in Latin America by Patel, A., Toro, W., Motrunich, A., El-Maghrabi, T., Esquerro, M.E., Dabbous, O.

Get full text

PCN129 A COST-UTILITY AND BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) IN MEXICO by Toro, W., Braun, S., Sanchez, L.A., Anaya, P.

Get full text

P79 Real-world outcomes of disease-modifying treatment for patients with spinal muscular atrophy: findings from a global retrospective chart review by Dabbous, O., LaMarca, N., Toro, W., Wallach, S., Mumneh, N., Aassi, M., O'Brien, E., Baranello, G., Reyna, S.

“…Disease-modifying treatments (DMTs; nusinersen, onasemnogene abeparvovec [OA], and risdiplam), have substantially improved prognoses for patients with spinal…”
Get full text

CO41 Real-World Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged ≥6 Months by Dabbous, O., Yang, M., Georgieva, M., Toro, W., LaMarca, N., Patel, A., Anderson, A., Akbarnejad, H., Reyna, S.P.

Get full text

POSC158 The Burden of Spinal Muscular Atrophy Type 1 (SMA1) on Caregivers in Japan: First Results of a Global Survey by Toro, W, Tanaka, S, Patel, A, Dabbous, O, Aballéa, S, Motrunich, A, Nomoto, M, Saito, K

Get full text

PCR262 Real-World Outcomes and Health Care Resource Utilization of Onasemnogene Abeparvovec for US Patients With Spinal Muscular Atrophy Type 2: Results of a Retrospective Chart Review Study by Dabbous, O, Yang, M, Georgieva, M, Toro, W, LaMarca, N, Patel, A, Anderson, A, Reyna, SP

Get full text

PCR61 The Burden of Spinal Muscular Atrophy Type 2 (SMA2) on Caregivers in Japan, United Kingdom, and United States: Results of a Global Survey by Toro, W, Tanaka, S, Patel, A, Dabbous, O, Motrunich, A, Aballéa, S, Toumi, M, El-Maghrabi, T, Saito, K

Get full text

SMA - TREATMENT by Gauthier-Loiselle, M., Cloutier, M., Toro, W., Patel, A., Shi, S., Davidson, M., Bischof, M., LaMarca, N., Dabbous, O.

Get full text

SMA - TREATMENT: EP.285 Nusinersen dosing patterns in US patients with spinal muscular atrophy (SMA) type 1: Findings from a retrospective claims database analysis by Gauthier-Loiselle, M., Cloutier, M., Toro, W., Patel, A., Shi, S., Davidson, M., Bischof, M., LaMarca, N., Dabbous, O.

Get full text

CN2 EVALUACIÓN DE COSTO-EFECTIVIDAD DE LA ENZALUTAMIDA (ENZA) FRENTE A LA ABIRATERONA (ABI) PARA EL TRATAMIENTO DE PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN METASTÁSICO (CPRCM) ANTES DEL USO DE DOCETAXEL EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS) by Gay, J.G., Toro, W., Braun, S.

Get full text

SMA - TREATMENT by Dabbous, O., Yang, M., Georgieva, M., Toro, W., LaMarca, N., Patel, A., Minkoff, N., Carley, C., Zhu, J., Anderson, A., Wu, E.

Get full text

SMA - TREATMENT: EP.292 Real-world outcomes of onasemnogene abeparvovec (OA) alone or with prior nusinersen in pediatric SMA: Interim analysis of a US chart review by Dabbous, O., Yang, M., Georgieva, M., Toro, W., LaMarca, N., Patel, A., Minkoff, N., Carley, C., Zhu, J., Anderson, A., Wu, E.

Get full text